369 related articles for article (PubMed ID: 22096241)
21. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts.
del Rey M; Benito R; Fontanillo C; Campos-Laborie FJ; Janusz K; Velasco-Hernández T; Abáigar M; Hernández M; Cuello R; Borrego D; Martín-Zanca D; De Las Rivas J; Mills KI; Hernández-Rivas JM
PLoS One; 2015; 10(5):e0126555. PubMed ID: 25955609
[TBL] [Abstract][Full Text] [Related]
22. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
23. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
24. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Wu SJ; Liu CY; Chen CY; Tseng MH; Huang CF; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Hsu SC; Ko BS; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Aug; 89(8):E109-15. PubMed ID: 24723457
[TBL] [Abstract][Full Text] [Related]
25. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract][Full Text] [Related]
26. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
[No Abstract] [Full Text] [Related]
27. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
[TBL] [Abstract][Full Text] [Related]
28. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
Visconte V; Avishai N; Mahfouz R; Tabarroki A; Cowen J; Sharghi-Moshtaghin R; Hitomi M; Rogers HJ; Hasrouni E; Phillips J; Sekeres MA; Heuer AH; Saunthararajah Y; Barnard J; Tiu RV
Leukemia; 2015 Jan; 29(1):188-95. PubMed ID: 24854990
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
[TBL] [Abstract][Full Text] [Related]
31. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
32. SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.
Visconte V; Tabarroki A; Rogers HJ; Hasrouni E; Traina F; Makishima H; Hamilton BK; Liu Y; O'Keefe C; Lichtin A; Horwitz L; Sekeres MA; Hsieh FH; Tiu RV
Haematologica; 2013 Sep; 98(9):e105-7. PubMed ID: 23831919
[No Abstract] [Full Text] [Related]
33. Development of a high-resolution melting analysis for the detection of the SF3B1 mutations.
Yang J; Qian J; Lin J; Yang XF; Qian W; Chen Q; Yao DM; Wang CZ; Chen XX; Xiao GF; Ma YJ
Genet Test Mol Biomarkers; 2013 Apr; 17(4):342-7. PubMed ID: 23390883
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
35. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
36. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
[TBL] [Abstract][Full Text] [Related]
37. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia.
Wang C; Sashida G; Saraya A; Ishiga R; Koide S; Oshima M; Isono K; Koseki H; Iwama A
Blood; 2014 May; 123(21):3336-43. PubMed ID: 24735968
[TBL] [Abstract][Full Text] [Related]
38. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
39. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
[No Abstract] [Full Text] [Related]
40. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]